MedPath

ProQR

🇳🇱Netherlands
Ownership
-
Established
2012-01-01
Employees
-
Market Cap
$163.3M
Website
http://www.proqr.com/

ProQR Advances RNA Editing Pipeline with Four Clinical Readouts Expected by 2026

ProQR Therapeutics is advancing its Axiomer™ RNA editing platform across liver and CNS programs, with its lead program AX-0810 for cholestatic diseases on track for CTA filing in Q2 2025.

© Copyright 2025. All Rights Reserved by MedPath